Reference health
Immunogenicity and Safety of the Booster BNT162b2 Vaccine in Patients with Axial Spondyloarthritis Treated with Biological Disease-Modifying Drugs
22/22 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
8 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 22 checked references that resolve
resolves10.1016/j.ijid.2020.03.017
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
resolves10.1097/BOR.0000000000000725
Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases
resolves10.1093/cid/ciab079
The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
resolves10.1056/NEJMoa2116597
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants
resolves10.1056/NEJMoa2101765
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
resolves10.1038/s41591-022-01699-1
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
resolves10.1136/annrheumdis-2021-220647
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
resolves10.1016/S2665-9913(21)00333-7
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
resolves10.1016/S2665-9913(21)00393-3
Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
resolves10.1136/bmj.39335.541782.AD
Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
resolves10.1177/1759720X18773726
Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria
resolves10.1136/bmjopen-2020-043004
Recommendations for SARS-CoV-2/COVID-19 testing: a scoping review of current guidance
resolves10.1097/TP.0000000000004021
Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein–specific T cells in Lung Transplant Recipients
resolves10.1056/NEJMoa2114583
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
resolves10.1016/S2665-9913(22)00069-8
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
resolves10.1136/rmdopen-2021-002008
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies
resolves10.1136/annrheumdis-2021-221558
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
resolves10.1016/S2214-109X(21)00593-3
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review
resolves10.1056/NEJMoa2118691
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
resolves10.1038/s41591-021-01377-8
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
resolves10.1038/s41591-021-01540-1
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
resolves10.1136/ard.2010.137216
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
The 8 references without a DOI — listed, not checked
no DOI — not checkedEffectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis
no DOI — not checkedEconomic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness
no DOI — not checkedEffectiveness and safety of SARS-CoV-2 vaccine in realworld studies: a systematic review and meta-analysis
no DOI — not checkedEULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update
no DOI — not checkedFive Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test
no DOI — not checkedCOVID-19 vaccine waning and effectiveness and sideeffects of boosters: a prospective community study from the ZOE COVID Study
no DOI — not checkedRisk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden
no DOI — not checkedSafety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.4147517"><img src="https://citestamp.com/citestamped/10.2139/ssrn.4147517/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.4147517)